REFERENCES
1. Digumarti R, Koyyala VP. Patterns of Care of Childhood Cancers in India [Internet]. Central Nervous System Tumors. IntechOpen; 2021 [cited 2022 Feb 1]. Available from: https://www.intechopen.com/chapters/75757 DOI: 10.5772/intechopen.96709
2. Radhakrishnan V, Howard S, Lam C. Pediatric cancers in India: The forgotten disease. Cancer Research, Statistics, and Treatment. 2021 Jan 1;4(1):6. DOI: 10.4103/crst.crst_375_20
3 Radhakrishnan V. Drug pricing: A major barrier to access to cancer care in India. Cancer Research, Statistics, and Treatment. 2021 Apr 1;4(2):195. DOI 10.4103/crst.crst_66_21
4 D’Souza V, Palatty P, George T, Adnan M, Rao S, Baliga M. Financial audit of wastage of anticancer drugs: Pilot study from a tertiary care center in India. Indian J Cancer. 2019;56(2):146. DOI: 10.4103/ijc.IJC_169_18
5 Erenay FS, Horton S. “Financial audit of wastage of anticancer drugs: Pilot study from a tertiary care center of India”: A commentary. Indian Journal of Cancer. 2019 Apr 1;56(2):99-100. DOI: 10.4103/ijc.IJC_125_19
6. Gopisankar M, Wahlang J, Jagtap V, Sarkar C, Purnima Devi L, Harris C. Cancer chemotherapy drug wastage in a tertiary care hospital in India—A 3‐month prospective and 1‐year retrospective study. Br J Clin Pharmacol. 2019 Oct;85(10):2428–35. DOI: https://doi.org/10.1111/bcp.14064
7. Truong J, Cheung MC, Mai H, Letargo J, Chambers A, Sabharwal M, et al. The impact of cancer drug wastage on economic evaluations: Economics of Cancer Drug Wastage. Cancer. 2017 Sep 15;123(18):3583–90. DOI: https://doi.org/10.1002/cncr.30807
8 Gilbar PJ, Chambers CR, Gilbar EC. Opportunities to significantly reduce expenditure associated with cancer drugs. Future Oncology. 2017 Jun;13(15):1311–22. DOI: https://doi.org/10.2217/fon-2017-0033
9 Boby JM, Rajappa S, Mathew A. Financial toxicity in cancer care in India: a systematic review. The Lancet Oncology. 2021 Dec 1;22(12):e541–9. DOI: . https://doi.org/10.1016/S1470-2045(21)00468-X
10 Hess LM, Cui ZL, Li XI, Oton AB, Shortenhaus S, Watson IA. Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States. Journal of Medical Economics. 2018 Aug 3;21(8):755–61. DOI: https://doi.org/10.1080/13696998.2018.1467918
11 Bach PB, Conti RM, Muller RJ, Schnorr GC, Saltz LB. Overspending driven by oversized single-dose vials of cancer drugs. BMJ. 2016 Feb 29;352:i788. DOI: https://doi.org/10.1136/bmj.i788
12 Liran O, Prus J, Gordon N, Almog V, Gruenewald T, Goldstein DA. A real-world analysis of cancer drug wastage due to oversized vials. Journal of the American Pharmacists Association. 2018 Nov;58(6):643–6. DOI: https://doi.org/10.1016/j.japh.2018.06.004
13 Khandelwal N, Duncan I, Ahmed T, Rubinstein E, Pegus C. Impact of Clinical Oral Chemotherapy Program on Wastage and Hospitalizations. JOP. 2011 May;7(3S):e25s–9s. DOI: DOI: 10.1200/JOP.2011.000301
15 Fasola G, Aprile G, Marini L, Follador A, Mansutti M, Miscoria M. Drug waste minimization as an effective strategy of cost-containment in Oncology. BMC Health Serv Res. 2014 Dec;14(1):57. DOI: https://doi.org/10.1186/1472-6963-14-57
16 Nass SJ, Lustig TA, Amankwah FK, Shortliffe EH, National Academies of Sciences, Engineering, and Medicine. Efforts to Reduce Discarded Weight-Based Drugs. InMedications in Single-Dose Vials: Implications of Discarded Drugs 2021 Feb 25. National Academies Press (US). DOI: DOI: 10.17226/25911
17 Fahrenbruch R, Kintzel P, Bott AM, Gilmore S, Markham R. Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association. JOP. 2018 Mar 1;14(3):e130–6. DOI: 10.1200/JOP.2017.025411